Get started
Author

Thays Blanchard

Observed institution: Scientific Centre of Monaco
ORCID: 0009-0006-6030-9079
Observed ORCID: 0009-0006-6030-9079
OpenAlex ID: A5030187762
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al. · Cancer Research Communications · 9
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
2024 · Célia Gotorbe, Fabien Segui, et al. · Current Oncology · 4
PDF
Figure S6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
FIGURE 3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 6 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 2 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Data from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
FIGURE 5 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S4 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Table S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Figure S8 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S3 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Figure S7 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Figure S1 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
PDF
Figure S7 from Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
2023 · William Echavidre, Jérôme Durivault, et al.
Works count: 20
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type